Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo

Documenti analoghi

• Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
  di: Jianhua Ma, et al.
  Pubblicazione: (2024)
• Correction to “Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS‐AP‐combo and SURPASS‐3”
  Pubblicazione: (2026)
• Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J‐mono and J‐combo studies
  di: Kazuya Fujihara, et al.
  Pubblicazione: (2024)
• Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
  di: Brandon K. Bergman, et al.
  Pubblicazione: (2025)
• Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis
  di: Masato Yoneda, et al.
  Pubblicazione: (2025)